Personalized cancer genomics: The road map to clinical implementation

Clinical Chemistry

Volumn 58, Issue 4, 2012, Pages 661-663

  Yousef, George M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTOME;

CANCER PATIENT; CHROMOSOME ABERRATION; COLORECTAL CANCER; GENE EXPRESSION; GENE MUTATION; GENOMICS; HUMAN; MELANOMA; METASTASIS; NEOPLASM; ONCOGENE H RAS; ONCOGENE N RAS; PROSTATE CANCER; SHORT SURVEY; TUMOR XENOGRAFT;

CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; GENOME, HUMAN; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859361169     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.181073     Document Type: Short Survey

References (5)

1. Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res 2010;8:1175-87.
2. Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer 2009;8:20.
3. Karagiannis GS, Pavlou MP, Diamandis EP. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol 2010;4:496-510.
4. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011;3:111ra121.
5. Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 2011;13:504-13.